Get the Stockscreener App
0.1198
0.66%
-0.0008
After Hours:
.12
0.0002
+0.17%
Zomedica Corp stock is traded at $0.1198, with a volume of 3.75M.
It is down -0.66% in the last 24 hours and down -4.39% over the past month.
Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. The company's lead drug product candidate is ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs. It is also developing ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies; ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism in cats; and ZM-011, a transdermal gel formulation of fluoxetine for the treatment of feline behavioral disorders, such as inappropriate urination. The company has a collaboration agreement with Celsee Diagnostics, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and with Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. Zomedica Pharmaceuticals Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.
See More
Previous Close:
$0.1206
Open:
$0.1203
24h Volume:
3.75M
Relative Volume:
0.71
Market Cap:
$117.40M
Revenue:
$25.19M
Net Income/Loss:
$-34.53M
P/E Ratio:
-3.3278
EPS:
-0.036
Net Cash Flow:
$-20.62M
1W Performance:
-0.75%
1M Performance:
-4.39%
6M Performance:
-12.04%
1Y Performance:
-6.48%
1-Day Range:
$0.1197
$0.1209
1-Week Range:
$0.1197
$0.122
52-Week Range:
$0.117
$0.1952
Zomedica Corp Stock (ZOM) Company Profile
Name
Zomedica Corp
Sector
Phone
734-369-2555
Address
100 Phoenix Drive, Suite 190, Ann Arbor, MI
Compare ZOM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZOM
Zomedica Corp
|
0.1198 | 117.40M | 25.19M | -34.53M | -20.62M | -0.036 |
|
ZTS
Zoetis Inc
|
160.46 | 71.85B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.08 | 45.58B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.06 | 44.58B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.74 | 19.18B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
128.60 | 13.67B | 612.78M | -86.37M | -62.91M | -0.87 |
Zomedica Corp Stock (ZOM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-06-23 | Initiated | Dawson James | Buy |
Zomedica Corp Stock (ZOM) Latest News
Observations on the Zomedica Corp (AMEX:ZOM) Growth Curve - US Post News
Zomedica Corp [ZOM] stock for 18,450 USD was acquired by Blair Anthony K - Knox Daily
ZOMZomedica Corp. Latest Stock News & Market Updates - StockTitan
Zomedica Relocates Headquarters, Cuts Costs by $200,000 Annually -February 12, 2025 at 09:15 am EST - Marketscreener.com
Zomedica Improves Efficiency and Cuts Costs by Moving to New Headquarters - ACCESS Newswire
Smart Money Move: Zomedica's New HQ Cuts Expenses in Half, Accelerates Path to Profits - StockTitan
Zomedica Announces Presentation of Clinical Data in Support of New Indications for PulseVet Shock Wave Therapy at Annual Meeting of American Association of Equine Practitioners - ACCESS Newswire
Zomedica to Present at H.C. Wainwright 24th Annual Global Investment Conference - ACCESS Newswire
Zomedica Corp [ZOM] Records 200-Day SMA of $0.1375 - Knox Daily
Zomedica Launches the TRUFORMA(R) Enhanced Endogenous ACTH Assay to aid in Equine PPID Diagnosis - ACCESS Newswire
Experts predict Zomedica Corp’s (ZOM) current quarter earnings growth rate - US Post News
Zomedica Corp (ZOM) rating initates by Dawson James - Knox Daily
Zomedica (NYSEAMERICAN:ZOM) Shares Up 1.6%Here's Why - MarketBeat
Zomedica Finalizes Acquisition of Veterinary Imaging Company Revo Squared - ACCESS Newswire
US Equestrian Names Zomedica’s PulseVet System as the Official Shock Wave Therapy of US Equestrian Team Veterinarians - ACCESS Newswire
Zomedica Enters Into Strategic Investment and Potential Collaboration for VetGuardian Monitoring Product Line - ACCESS Newswire
Zomedica Announces Publication of Case Series Highlighting Success with PulseVet(R) Shock Wave Therapy for Difficult to Treat Fibrotic Myopathy in Working Dogs - ACCESS Newswire
Zomedica Expands International Reach with CE Certification for VetGuardian(R) System - ACCESS Newswire
Zomedica Increases Manufacturing Capacity with Expansion of its Roswell, Georgia Facility; Can Support Production to Five times Current Levels - ACCESS Newswire
Zomedica to Present at the NobleCon20 Twentieth Annual Emerging Growth Equity Conference December 4, 2024 - ACCESS Newswire
Zomedica Launches Ear Cytology Quick Scan Protocol for TRUVIEW(TM) Digital Microscope & Telepathology Platform - ACCESS Newswire
Zomedica Continues Global Expansion Through Strategic Partnership with SIRE Veterinario, S.A for Sales Expansion in Central America - ACCESS Newswire
Zomedica Completes Renovation & Upgrade of Manufacturing, Distribution, and R&D Center in Plymouth, Minnesota - ACCESS Newswire
Zomedica's Assisi Loop(R) Product Line Designated as Fear Free(TM) Preferred Product - ACCESS Newswire
Zomedica to Report Third Quarter 2024 Financial Results and Provide Business Update on November 7th at 4:30 p.m. ET - ACCESS Newswire
Zomedica to Present at the Sidoti Micro Cap Conference November 14, 2024 - ACCESS Newswire
Zomedica Appoints Scott A. Jordan Executive Vice President, Finance & Chief Financial Officer - ACCESS Newswire
Zomedica Announces Presentation of Compelling TRUFORMA(R) Research Findings and Educational Programs at Major Veterinary Internal Medicine Conference - ACCESS Newswire
Zomedica Announces License & Supply Agreement with Cresilon Inc. to Market and Sell Vetigel(R) Hemostatic Gel in the Animal Health Market - ACCESS Newswire
Zomedica Announces Expansion of Exclusive Equine Distribution Agreement with Grovet in Europe - ACCESS Newswire
A Bull Market Continues To Unfold On Zomedica Corp (AMEX: ZOM), As It Continued To Rise 3.67% In Year-To-Date - Marketing Sentinel
Zomedica Announces Third Quarter 2024 Financial Results: Revenue Up 10% to $7 Million; 72% Gross Margin, and $78 Million in Liquidity to Support Growth - ACCESS Newswire
Zomedica Reports Record Revenue of $7.3 Million for the Fourth Quarter and $25.2 Million for the Full Year 2023, Reflecting 33% Annual Growth; 69% Gross Margin and $100.5 Million in Liquidity - ACCESS Newswire
Noble Capital Markets Initiates Equity Research Coverage on Zomedica - ACCESS Newswire
Zomedica (NYSEAMERICAN:ZOM) Stock Price Down 2.2% – Here’s What Happened - Defense World
Geode Capital Management LLC Buys 321,395 Shares of Zomedica Corp. (NYSEAMERICAN:ZOM) - Defense World
Zomedica (NYSEAMERICAN:ZOM) Stock Price Down 2.2% – Here’s Why - Defense World
Zomedica (NYSEAMERICAN:ZOM) Shares Down 2.2%Should You Sell? - MarketBeat
Zomedica enters license and supply agreement with Cresilon Inc. - DVM 360
Zomedica Secures Exclusive U.S. Rights to Revolutionary Vetigel Bleeding Control Technology - StockTitan
Zomedica Unveils New Canine Tests Offering Faster Diagnostics for Heart and Breeding Health - AOL
Zomedica Launches Two New Quantitative Assays on the TRUFORMA(R) Platform: Canine NT-proBNP and Progesterone - AccessWire
Zomedica Expands TRUFORMA Platform with Breakthrough 20-Minute Cardiac and Breeding Diagnostic Tests - StockTitan
Zomedica appoints Scott Jordan as EVP, finance & CFO - MSN
Zomedica (NYSEAMERICAN:ZOM) Trading Down 2.8% – Here’s Why - Defense World
Zomedica Strengthens Leadership: Industry Veteran with 30+ Years Experience Named New CFO - StockTitan
Zomedica (NYSEAMERICAN:ZOM) Trading Down 2.8%Should You Sell? - MarketBeat
Zomedica CEO to Present at NobleCon20 Conference, Investor Meetings Scheduled - StockTitan
Zomedica secures new lease for headquarters expansion By Investing.com - Investing.com South Africa
Zomedica secures new lease for headquarters expansion - Investing.com
Noble Financial Predicts Zomedica FY2024 Earnings - MarketBeat
Zomedica Corp Stock (ZOM) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.23%
3.94%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):